Does BPC-157 cause cancer — or is that claim being oversimplified?

In this episode of Peptides Explained, we take a study-review approach to one of the biggest concerns surrounding BPC-157: its potential angiogenic effects and whether that could theoretically contribute to cancer proliferation.

Angiogenesis means new blood vessel formation. It is essential for normal wound healing and tissue repair, but it also plays a role in tumor biology. That overlap has led to concerns that BPC-157 could “feed” cancer growth.

But what do the studies actually show?

In this episode, we review key papers on BPC-157, including:

• Hsieh et al., 2017 — VEGFR2 activation and angiogenesis
• Radeljak, Seiwerth, and Sikiric, 2004 — melanoma cell-line data
• Kang et al., 2018 — cancer cachexia context
• Masnec et al., 2015 — corneal injury and neovascularization

We break down the difference between physiologic repair signaling and pathologic tumor angiogenesis, and explain why the current evidence does not support the simple claim that BPC-157 causes cancer proliferation.

That said, the lack of strong human oncology safety data means caution is still appropriate, especially for anyone with active cancer, prior cancer, unexplained symptoms, or elevated cancer risk.

This episode is designed as a literature review for clinicians, physicians, and scientifically curious listeners who want a balanced, evidence-based explanation.

Disclaimer: This content is for informational and educational purposes only and is not medical advice. Always consult a licensed healthcare professional before considering any therapy.

Affiliate disclosure: Peptides Explained is an affiliate partner with OfflinePeptides.com. If you use my link, I may earn a commission at no additional cost to you.
https://offlinepeptides.com/ref/JohnGarrett/

#BPC157 #PeptidesExplained #CancerRisk #Angiogenesis #PeptideScience #VEGF #TissueRepair #MedicalEducation #PhysicianReview #Peptides